564
Participants
Start Date
May 14, 2007
Primary Completion Date
December 26, 2008
Study Completion Date
December 26, 2008
Ronacaleret
100mg, 200mg, 300mg, 400mg
Teriparatide
PTH (1-34)
Alendronate
Bisphosphonate
GSK Investigational Site, Buenos Aires
GSK Investigational Site, St Leonards
GSK Investigational Site, Rosebank
GSK Investigational Site, Hamar
GSK Investigational Site, Ballerup Municipality
GSK Investigational Site, Footscray
GSK Investigational Site, Heidelberg
GSK Investigational Site, Geelong
GSK Investigational Site, Tienen
GSK Investigational Site, Liège
GSK Investigational Site, Bergen
GSK Investigational Site, Somerset West
GSK Investigational Site, Panorama
GSK Investigational Site, Ghent
GSK Investigational Site, Berlin
GSK Investigational Site, Berlin
GSK Investigational Site, Berlin
GSK Investigational Site, Berlin
GSK Investigational Site, Mexico City
GSK Investigational Site, Santiago de Compostela
GSK Investigational Site, Santiago de Compostela
GSK Investigational Site, Duncansville
GSK Investigational Site, Bethesda
GSK Investigational Site, Hamburg
GSK Investigational Site, Hamburg
GSK Investigational Site, Madrid
GSK Investigational Site, Madrid
GSK Investigational Site, Decatur
GSK Investigational Site, Cleveland
GSK Investigational Site, Akron
GSK Investigational Site, Frankfurt am Main
GSK Investigational Site, Palm Desert
GSK Investigational Site, Walnut Creek
GSK Investigational Site, Oakland
GSK Investigational Site, Portland
GSK Investigational Site, Moscow
GSK Investigational Site, Moscow
GSK Investigational Site, Ciudad Autónoma de Buenos Aires
GSK Investigational Site, Buenos Aires
GSK Investigational Site, Hong Kong
GSK Investigational Site, Shatin
GSK Investigational Site, Oslo
GSK Investigational Site, Grudziądz
GSK Investigational Site, Warsaw
GSK Investigational Site, Wroclaw
GSK Investigational Site, Seoul
GSK Investigational Site, Suwon
GSK Investigational Site, Barcelona
GSK Investigational Site, Barcelona
Lead Sponsor
GlaxoSmithKline
INDUSTRY